All In Biotech

Drug Trial Radar · NCT07202897

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain: A Randomized Multicenter Trial

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

532

Planned (sponsor's estimate)

Start

Jan 7, 2026

Primary completion

Jan 7, 2032

Study completion Jan 7, 2033

Sponsor

Lead sponsor
Rennes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypertrophic cardiomyopathy (HCM) is a common (\> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death. Observational studies have been conducted to search for parameters which correlate with the risk of AF (P wave duration and supra-ventricular burst on the Holter-ECG monitoring, L-wave morphology, degree of hypertrophy, clinical parameters-comorbidities, and size of the left atrium) with no real impact on clinical management. Left Atrial strain (LA-strain) has been recently demonstrated relevant (for instance our pilot work (for predicting stroke and/or AF (a cut-off of 15% is highly specific, 20% being the optimal cut-off). LA-strain (cut-off 20%) could be used for defining the patients that might require preventive anticoagulation therapy. A randomized clinical trial is needed to extend the use of anticoagulation therapy to patients in sinus rhythm but identified to be at risk for AF. Of note, it has been demonstrated that in this population, stroke occurred in 67% of the patients without any clinical atrial arrhythmia.

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Interventions

  • Anticoagulant treatment RivaroxabanDrug

    Anticoagulant treatment Rivaroxaban in addition to best medical therapy

  • Best medical therapyOther

    Best medical therapy alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. all-cause death, myocardial infarction, stroke and systemic embolismTime frame: 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Angers

    Angers, France · Not yet recruiting

  • CHU Bordeaux Haut-Levêque

    Bordeaux, France · Not yet recruiting

  • CHU Brest - Hôpital La Cavale Blanche

    Brest, France · Not yet recruiting

  • CHU Caen

    Caen, France · Not yet recruiting

  • CHU Dijon - Hôpital François Mitterrand

    Dijon, France · Recruiting

  • CHU Grenoble Alpes

    Grenoble, France · Not yet recruiting

  • CHU Lille

    Lille, France · Not yet recruiting

  • APHM - Hôpital La Timone

    Marseille, France · Not yet recruiting

  • CHU de Nantes -Hôpital Nord Laennec

    Nantes, France · Not yet recruiting

  • AP-HP Höpital la Pitié-Salpétrière

    Paris, France · Not yet recruiting

  • APHP Hopital Européen Georges Pompidou

    Paris, France · Not yet recruiting

  • APHP, Hôpital Lariboisière

    Paris, France · Not yet recruiting

  • CHU Rennes - Hôpital Pontchaillou

    Rennes, France · Recruiting

  • CHU de Rouen

    Rouen, France · Not yet recruiting

  • CHU Rangueil Toulouse

    Toulouse, France · Not yet recruiting

  • CHU de TOURS - HOPITAL TROUSSEAU

    Tours, France · Not yet recruiting

  • CHU Nancy

    Vandœuvre-lès-Nancy, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.